Plain-English translation of NCT03151473 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a long-term observational study that enrolls up to 20,000 Chinese adults with fatty liver disease. Researchers will follow participants over time to learn more about how the disease develops, progresses, and affects people differently.
Fatty liver disease is increasingly common in China and around the world, but doctors don't yet fully understand why some people develop severe liver damage (called NASH) while others don't. This study aims to fill that gap by following a large group of patients and gathering information about who is at highest risk for complications.
You likely qualify if…
You likely don't qualify if…
You would be followed by a team of researchers over an extended period as part of a large registry. During your participation, you would share your medical information and allow researchers to monitor your liver health through standard clinical care. The study does not involve taking a new medication — instead, it tracks what happens to people with fatty liver disease over time to improve understanding and future treatments.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Hong Kong
Enrollment target
~20,000 participants
Started
May 2017
Primary completion
May 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yudong Wang, PhD
Humanity and Health Research Centre
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.